Predicting gadolinium enhancement status in MS patients eligible for randomized clinical trials
Article 2005 en
Authors
FB
Frederik Barkhof
UH
Ulrike Held
JS
Jack H. Simon
Abstract
1 min read
Gadolinium status can be predicted by a set of baseline variables, certainly when T2 burden of disease is included. These findings may benefit the design and statistical power of future randomized clinical trials.
Josep M. Llovet, Adrian M. Di Bisceglie, Jordi Bruix, Barnett S. Kramer, Riccardo Lencioni, Andrew X. Zhu, Morris Sherman, Myron Schwartz, Michael T. Lotze, Jayant A. Talwalkar, Gregory J. Gores
Elliot M. Frohman, Douglas S. Goodin, Peter A. Calabresi, John R. Corboy, Patricia K. Coyle, Massimo Filippi, Joseph A. Frank, Steven Galetta, Robert I. Grossman, Kathleen Hawker, Norman J. Kachuck, Michael C. Levin, J. Theodore Phillips, Michael K. Racke, Victor M. Rivera, W. H. Stuart
Massimo Filippi, Tarek Yousry, A. Campi, Christoph Kandziora, Bruno Colombo, Raymond Voltz, Vittorio Martinelli, Simone Spuler, S. Bressi, Giuseppe Scotti, Gıancarlo Comı
Discussion(0)
No comments yet. Be the first to comment.